Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

To the State Secretary of
Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

2021041173

National Health Care Institute
Care
Medicinal Products

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Our reference
2021041173

Date 26 October 2021
Subject Package advice ponesimod (Ponvory®)

Dear Mr Blokhuis,

In your letter of 15 September 2021 (CIBG-21-02477), you asked the National Health Care Institute to assess whether the product ponesimod (Ponvory®) can be included in the Medicine Reimbursement System (GVS).
Ponesimod is available as a film-coated tablet in various doses ranging from 2 mg to 20 mg and is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
We have handled this request by means of a marginal assessment. The considerations are included in the GVS report attached to this letter.

Conclusion of the marginal assessment
Based on the criteria for interchangeability, it can be concluded that ponesimod (Ponvory®) is interchangeable with the other medicinal products in the GVS cluster 0N07XXCO V, which includes: ozanimod (Zeposia®), teriflunomide (Aubagio®) and dimethyl fumarate (Tecfidera®).

Advice
We advise you to include ponesimod on List 1A in cluster 0N07XXCO V of the GVS. The standard dose for ponesimod can be set at 20 mg.

Yours sincerely,

Sjaak Wijma
Chair of the Executive Board